Revaccination of Children after Completion of Standard Chemotherapy for Acute Leukemia

Patel, Soonie R.; Ortín, Miguel; Cohen, B. J.; Borrow, Ray; Irving, Diane; Sheldon, Joanne E.; Heath, Paul T

doi:10.1086/511636

Cited by 102 publications

(107 citation statements)

References 39 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We agree with the recommendation of many others that ALL patients should be re-vaccinated following completion of chemotherapy [3,6,21,24]. Only Fioredda et al [23] considered administration of another complete vaccination schedule to each ALL subject over treatment taking into account the economical aspect of vaccines and laboratory kits.…”

Section: Post-chemotherapy Vaccination Recommendations For Allsupporting

confidence: 60%

“…In Nilsson et al's [6] study 14 ALL patients without immunity against measles were re-vaccinated after chemotherapy and only 8 patients (57%) responded. Patel et al [21] reported higher re-vaccination responses (94%) in patients with ALL and AML.…”

Section: Post-chemotherapy Vaccination Recommendations For Allmentioning

confidence: 98%

“…Patel et al [21] found even higher rates of protective antibodies in patients with ALL and acute myeloblastic leukemia (AML). He reported protective anti-tetanus antibodies in 100% of the patients after chemotherapy.…”

Section: Protective Antibody Levels Against Tetanusmentioning

confidence: 99%

“…Patel et al [21] recommended one booster dose 6 months after completion of chemotherapy in their study of 59 children with ALL and AML. Optimal post-vaccination levels were achieved in 100%, 93%, and 94% of the patients with single dose of tetanus, Hib, and measles rePediatr Blood Cancer DOI 10.1002/pbc Median protective antibody levels are written bold.…”

Section: Post-chemotherapy Vaccination Recommendations For Allmentioning

confidence: 99%

See 3 more Smart Citations

Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re‐vaccination

Zengin

Sarper

2009

Pediatric Blood & Cancer

View full text Add to dashboard Cite

ObjectiveLoss of immunity to previous vaccination and timing of re‐vaccination in children receiving chemotherapy remains controversial. The aim of this study was to investigate the immunity to vaccine preventable diseases in children with acute lymphoblastic leukemia (ALL).ProcedureSixty‐one patients with ALL and 13 healthy siblings were enrolled. Three study groups included newly diagnosed patients (group 1), patients on maintenance chemotherapy (group 2), and patients that completed chemotherapy (group 3). Blood samples for baseline antibody titers were obtained from all the patients and controls. Patients in group 2 were vaccinated with diphtheria, tetanus, and hemophilus influenzae type b (Hib). Patients in group 3 and controls received the measles vaccine in addition to all the above vaccines. In groups 2 and 3, post‐vaccination antibody titers were also obtained.ResultsPatients and controls had no Hib vaccine during primary vaccination. After chemotherapy median antibody levels against diphtheria, tetanus, measles, and Hib were decreased but tetanus antibodies were still at the protective levels. Proportions of the patients with protective levels were 11.1%, 83.3%, 16.7%, and 16.7% for diphtheria, tetanus, Hib, and measles, respectively. Vaccination achieved protective antibody levels in 81%, 100%, 89.5%, and 70% of the patients for diphtheria, tetanus, Hib, and measles, respectively. Vaccine responses during maintenance were also satisfying.ConclusionWe recommend re‐vaccination after 3 months of cessation of chemotherapy. Administration of Hib vaccine may be beneficial after the first 3 months of maintenance chemotherapy especially in children with no primary vaccination followed by a second booster dose after cessation of therapy to increase immunity. Pediatr Blood Cancer 2009;53:967–972. © 2009 Wiley‐Liss, Inc.

show abstract

Section: Post-chemotherapy Vaccination Recommendations For Allsupporting

confidence: 60%

Section: Post-chemotherapy Vaccination Recommendations For Allmentioning

confidence: 98%

Section: Protective Antibody Levels Against Tetanusmentioning

confidence: 99%

Section: Post-chemotherapy Vaccination Recommendations For Allmentioning

confidence: 99%

See 2 more Smart Citations

Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re‐vaccination

Zengin

Sarper

2009

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…With reference to vaccine response, Patel et al reported antibody response to MMR vaccine in more than 94% of children who had completed standard chemotherapy for acute leukemia, without adverse reactions. 72 …”

Section: Live Attenuated Vaccinesmentioning

confidence: 99%

Practical review of immunizations in adult patients with cancer

Ariza-Heredia¹,

Chemaly²

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Loss of humoral immunity in childhood cancer survivors not having undergone hematopoietic stem cell transplantation

Pearson,

Pulley,

Diniz

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundData are limited and conflicting regarding loss of immunity in childhood cancer survivors who did not undergo hematopoietic stem cell transplantation. The purpose of this retrospective, single center study is to provide further data to help build unifying revaccination guidelines post‐chemotherapy in childhood cancer survivors not having undergone hematopoietic stem cell transplantation.MethodsThis retrospective study included 28 childhood cancer survivors, 14 males and 14 females, whose treatment consisted of at least 3 months of chemotherapy and with confirmation of completing their primary vaccination series prior to therapy. The rate of vaccine titer seropositivity for cancer survivors was compared with the expected general population, based on long‐term studies of anti‐body persistence.ResultsDecreased seropositivity for measles, mumps, rubella, varicella, tetanus, and hepatitis B was found in patients across all categories of malignancy compared with the general population. However, tetanus was not statistically significant. Results were more pronounced for those with hematological malignancies.ConclusionsThis study indicates that pediatric cancer survivors, especially those with hematological malignancies, may have greater loss of protective antibodies from primary vaccinations. Further studies are needed to provide guidelines for revaccination of both hematologic malignancies and solid tumor childhood cancer survivors who did not undergo hematopoietic stem cell transplantation.

show abstract

Revaccination of Children after Completion of Standard Chemotherapy for Acute Leukemia

Abstract: Revaccination of children after standard chemotherapy is important, and protection can be achieved in the majority of these children using a simple schedule of 1 vaccine dose at 6 months after completion of leukemia therapy.

Cited by 102 publications

References 39 publications

Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re‐vaccination

Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re‐vaccination

Practical review of immunizations in adult patients with cancer

Loss of humoral immunity in childhood cancer survivors not having undergone hematopoietic stem cell transplantation

Contact Info

Product

Resources

About